Full Text Journal Articles by
Author Jean Rommelaere

Advertisement

Find full text journal articles






Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.

Irina Kiprianova, Alexandra Just, Barbara Leuchs, Jean Rommelaere, Assia L Angelova,

Fluorescence in situ hybridization (FISH) is a specific, sensitive, accurate, and reliable technique widely applied in both research and clinic. Here we describe the detailed protocol of a FISH method established by us to serve the scientific purposes of the first oncolytic parvovirus clinical trial (ParvOryx01). This trial was launched ... Read more >>

Methods Mol. Biol. (Methods in molecular biology (Clifton, N.J.))
[2020, 2058:295-306]

Cited: 0 times

View full text PDF listing >>



Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.

Assia Angelova, Jean Rommelaere,

Rodent protoparvoviruses (PVs), parvovirus H-1 (H-1PV) in particular, are naturally endowed with oncolytic properties. While being historically described as agents that selectively replicate in and kill cancer cells, recent yet growing evidence demonstrates that these viruses are able to reverse tumor-driven immune suppression through induction of immunogenic tumor cell death, ... Read more >>

Viruses (Viruses)
[2019, 11(5):]

Cited: 3 times

View full text PDF listing >>



Advertisement

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.

Katrin Goepfert, Christiane Dinsart, Jean Rommelaere, Friedrich Foerster, Markus Moehler,

The recent therapeutic success of immune checkpoint inhibitors in the treatment of advanced melanoma highlights the potential of cancer immunotherapy. Oncolytic virus-based therapies may further improve the outcome of these cancer patients. A human ex vivo melanoma model was used to investigate the oncolytic parvovirus H-1 (H-1PV) in combination with ... Read more >>

Front Oncol (Frontiers in oncology)
[2019, 9:425]

Cited: 0 times

View full text PDF listing >>



ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE.

Karsten Geletneky, Andreas Bartsch, Christian Weiss, Helga Bernhard, Antonio Marchini, Jean Rommelaere,

AbstractBACKGROUNDCombination therapy is an emerging concept to improve the clinical effects of oncolytic virus based anti-cancer strategies. In a phase I/IIa trial (ParvOryx01) the oncolytic H-1 parvovirus (H-1PV) induced markers of immune activation in patients with recurrent glioblastoma. The goal of this investigation was to enhanced H-1PV efficiency by combination ... Read more >>

Neuro-oncology (Neuro-oncology)
[2018, 20(Suppl 6):vi10-vi10]

Cited: 0 times

View full text PDF listing >>



Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.

Marie-Laure Plissonnier, Sylvie Fauconnet, Hugues Bittard, Christiane Mougin, Jean Rommelaere, Isabelle Lascombe,

Known activators of the Peroxisome Proliferator-Activated Receptor γ (PPARγ), thiazolidinediones (TZD) induce apoptosis in a variety of cancer cells through dependent and/or independent mechanisms of the receptor. We tested a panel of TZD (Rosiglitazone, Pioglitazone, Ciglitazone) to shed light on their potential therapeutic effects on three cervical cancer cell lines ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(64):107744-107762]

Cited: 0 times

View full text PDF listing >>



Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors.

Andreas Jungmann, Barbara Leuchs, Jean Rommelaere, Hugo A Katus, Oliver J Müller,

Adeno-associated virus vectors are a powerful tool for gene transfer approaches. We have established a simple and fast plasmid-based production system for achieving high adeno-associated virus titers within 6 working days. The same procedure can be used for all serotypes and thus allows direct comparability of different serotypes. In this ... Read more >>

Hum Gene Ther Methods (Human gene therapy methods)
[2017, 28(5):235-246]

Cited: 5 times

View full text PDF listing >>



Protocol for efficient generation and characterization of adeno-associated viral (AAV) vectors.

Andreas Jungmann, Barbara Leuchs, Hugo A Katus, Jean Rommelaere, Oliver J Müller,

AAV vectors are a powerful tool for gene transfer approaches. We have established a simple and fast plasmid-based production system for achieving high AAV titers within 6 working days. The same procedure can be used for all serotypes and thus allows direct comparability of different serotypes. In this protocol we ... Read more >>

Hum Gene Ther Methods (Human gene therapy methods)
[2017, :]

Cited: 0 times

View full text PDF listing >>



Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.

Assia L Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg, Jean Rommelaere,

Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently developed and are currently under preclinical and clinical investigation. Oncolytic viruses, including the autonomous ... Read more >>

Viruses (Viruses)
[2017, 9(12):]

Cited: 9 times

View full text PDF listing >>



Virotherapy Research in Germany: From Engineering to Translation.

Guy Ungerechts, Christine E Engeland, Christian J Buchholz, Jürgen Eberle, Henry Fechner, Karsten Geletneky, Per Sonne Holm, Florian Kreppel, Florian Kühnel, Karl Sebastian Lang, Mathias F Leber, Antonio Marchini, Markus Moehler, Michael D Mühlebach, Jean Rommelaere, Christoph Springfeld, Ulrich M Lauer, Dirk M Nettelbeck,

Virotherapy is a unique modality for the treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Various viruses are being developed as OVs preclinically and clinically, several of them engineered to encode therapeutic proteins for tumor-targeted gene therapy. ... Read more >>

Hum. Gene Ther. (Human gene therapy)
[2017, 28(10):800-819]

Cited: 7 times

View full text PDF listing >>



Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.

Christiane Dinsart, Kalliopi Pervolaraki, Alexandra Stroh-Dege, Muriel Lavie, Isabelle Ronsse, Jean Rommelaere, Jo Van Damme, Katrien Van Raemdonck, Sofie Struyf,

Application of oncolytic viruses is a valuable option to broaden the armament of anticancer therapies, as these combine specific cytotoxic effects and immune-stimulating properties. The self-replicating H-1 parvovirus (H-1PV) is a prototypical oncolytic virus that, besides targeting tumor cells, also infects endothelial cells, thus combining oncolytic and angiostatic traits. To ... Read more >>

Hum. Gene Ther. (Human gene therapy)
[2017, 28(3):295-306]

Cited: 5 times

View full text PDF listing >>



Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Anette Heller, Assia L Angelova, Sonja Bauer, Svitlana P Grekova, Marc Aprahamian, Jean Rommelaere, Michael Volkmar, Johannes W G Janssen, Nathalie Bauer, Ingrid Herr, Thomas Giese, Matthias M Gaida, Frank Bergmann, Thilo Hackert, Stefan Fritz, Nathalia A Giese,

Our aim was to establish and characterize a novel pancreatic ductal adenocarcinoma cell line from a patient in whom the origin of the invasive carcinoma could be traced back to the intraductal papillary mucinous neoplasm (IPMN) precursor lesion.The primary patient-derived tumor was propagated in immunocompromised mice for 2 generations and ... Read more >>

Pancreas (Pancreas)
[2016, 45(10):1452-1460]

Cited: 6 times

View full text PDF listing >>



HG-87COMBINED APPLICATION OF TEMOZOLOMIDE AND THE ONCOLYTIC PARVOVIRUS H-1 INCREASES CYTOTOXIC EFFECTS IN CELL CULTURE AND ANIMAL MODELS OF PEDIATRIC GLIOBLASTOMA.

Jeannine Lacroix, Rafael Josupeit, Domenico Sorrentino, Carsten Geiss, Barbara Leuchs, Pascal Johann, Jacques Grill, Olaf Witt, Jean Rommelaere, Christiane Dinsart,

Neuro-oncology (Neuro-oncology)
[2016, 18(Suppl 3):iii68-iii68]

Cited: 0 times

View full text PDF listing >>



ATNT-07FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB.

Karsten Geletneky, Assia Angelova, Barbara Leuchs, Andreas Bartsch, David Capper, Jacek Hajda, Jean Rommelaere,

Neuro-oncology (Neuro-oncology)
[2015, 17(Suppl 5):v11-v11]

Cited: 0 times

View full text PDF listing >>



The Promise of Gene Therapy for Pancreatic Cancer.

Georges Vassaux, Assia Angelova, Patrick Baril, Patrick Midoux, Jean Rommelaere, Pierre Cordelier,

Unlike for other digestive cancer entities, chemotherapy, radiotherapy, and targeted therapies have, so far, largely failed to improve patient survival in pancreatic adenocarcinoma (PDAC), which remains the fourth leading cause of cancer-related death in Europe and the United States. In this context, gene therapy may offer a new avenue for ... Read more >>

Hum. Gene Ther. (Human gene therapy)
[2016, 27(2):127-133]

Cited: 6 times

View full text PDF listing >>



A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules.

Antonella Borrelli, Antonietta Schiattarella, Roberto Mancini, Alessandra Pica, Maria Laura Pollio, Maria Grazia Ruggiero, Patrizia Bonelli, Viviana De Luca, Franca Maria Tuccillo, Clemente Capasso, Enrico Gori, Marina Sanseverino, Andrea Carpentieri, Leila Birolo, Piero Pucci, Jean Rommelaere, Aldo Mancini,

A 24-amino acid leader peptide of a new human recombinant manganese superoxide dismutase can enter cells and carry molecules. Here, we demonstrated that six of the 24 amino acids penetrate cells through a particular gate represented by a specific amino acid sequence of the oestrogen receptor (ER). We analysed the ... Read more >>

Sci Rep (Scientific reports)
[2016, 6:18691]

Cited: 3 times

View full text PDF listing >>



Double-faceted mechanism of parvoviral oncosuppression.

Karsten Geletneky, Jürg Pf Nüesch, Assia Angelova, Irina Kiprianova, Jean Rommelaere,

The H-1 parvovirus (H-1PV) exerts oncosuppressive action that has two components: oncotoxicity and immunostimulation. While many human tumor cells, including conventional drug-resistant ones, can be killed by H-1PV, some fail to support progeny virus production, necessary for infection propagation in neoplastic tissues. This limitation can be overcome through forced selection ... Read more >>

Curr Opin Virol (Current opinion in virology)
[2015, 13:17-24]

Cited: 13 times

View full text PDF listing >>



The Minute Virus of Mice NS2 proteins are not essential for productive infection of embryonic murine cells in utero.

Saar Tal, Michal Mincberg, Irina Rostovsky, Jean Rommelaere, Nathali Salome, Claytus Davis,

The P4 promoter of the autonomous parvovirus Minute Virus of Mice (MVM) drives the production of its non-structural proteins, NS1 and NS2. The NS2 isoforms are without enzymatic activity but interact with cellular proteins. While NS2 is crucial to the viral life cycle in cultured murine cells, NS2-null mutant virus ... Read more >>

Virology (Virology)
[2014, 468-470:631-636]

Cited: 0 times

View full text PDF listing >>



Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Markus Moehler, Katrin Goepfert, Bernd Heinrich, Caroline J Breitbach, Maike Delic, Peter Robert Galle, Jean Rommelaere,

Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check points may help to overcome the immune silencing induced ... Read more >>

Front Oncol (Frontiers in Oncology)
[2014, 4:92]

Cited: 16 times

View full text PDF listing >>



Tumor suppressing properties of rodent parvovirus NS1 proteins and their derivatives.

Jürg P F Nüesch, Jean Rommelaere,

Cancer chemotherapy with monospecific agents is often hampered by the rapid development of tumor resistance to the drug used. Therefore, combination treatments aiming at several different targets are sought. Viral regulatory proteins, modified or not, appear ideal for this purpose because of their multimodal killing action against neoplastically transformed cells. ... Read more >>

Adv. Exp. Med. Biol. (Advances in experimental medicine and biology)
[2014, 818:99-124]

Cited: 9 times

View full text PDF listing >>



Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.

Muriel Lavie, Sofie Struyf, Alexandra Stroh-Dege, Jean Rommelaere, Jo Van Damme, Christiane Dinsart,

Anti-angiogenic therapy has been recognized as a powerful potential strategy for impeding the growth of various tumors. However no major therapeutic effects have been observed to date, mainly because of the emergence of several resistance mechanisms. Among novel strategies to target tumor vasculature, some oncolytic viruses open up new prospects. ... Read more >>

Virology (Virology)
[2013, 447(1-2):221-232]

Cited: 5 times

View full text PDF listing >>



Parvoviruses-tools to fine-tune anticancer immune responses.

Svitlana P Grekova, Jean Rommelaere, Zahari Raykov,

Oncolytic virotherapy represents a recent approach to anticancer therapy. Rodent autonomous parvoviruses (PVs) represent naturally oncolytic viruses that are non-pathogenic for humans but possess and extended tropism, being capable of infecting transformed cells of both rodent and human origin. Recent work from our group demonstrate that PVs can act as ... Read more >>

Oncoimmunology (Oncoimmunology)
[2012, 1(8):1417-1419]

Cited: 5 times

View full text PDF listing >>



Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells.

Yuan Yuan Wang, Jiong Liu, Qing Zheng, Zhi Hua Ran, Nathalie Salomé, Michèle Vogel, Jean Rommelaere, Shu Dong Xiao, Zheng Wang,

OBJECTIVE: To investigate the in vivo oncosuppressive effect of the non-structural protein NS1 of parvovirus H-1 on human gastric cancer cell lines. METHODS: Recombinant plasmid pcDNA3.1-NS1 containing the complete NS1 gene of parvovirus H-1 was constructed and characterized by restriction enzyme digestion and sequence analysis. The human gastric cancer cell ... Read more >>

J Dig Dis (Journal of digestive diseases)
[2012, 13(7):366-373]

Cited: 8 times

View full text PDF listing >>



Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.

Karsten Geletneky, Johannes Huesing, Jean Rommelaere, Joerg R Schlehofer, Barbara Leuchs, Michael Dahm, Ottheinz Krebs, Magnus von Knebel Doeberitz, Bernard Huber, Jacek Hajda,

The treatment of patients with malignant brain tumors remains a major oncological problem. The median survival of patients with glioblastoma multiforme (GBM), the most malignant type, is only 15 months after initial diagnosis and even less after tumor recurrence. Improvements of standard treatment including surgery and radio-chemotherapy have not lead ... Read more >>

BMC Cancer (BMC Cancer)
[2012, 12:99]

Cited: 76 times

View full text PDF listing >>



Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.

Sebastian Dempe, Muriel Lavie, Sofie Struyf, Rauf Bhat, Hannelien Verbeke, Stephanie Paschek, Nele Berghmans, Renate Geibig, Jean Rommelaere, Jo Van Damme, Christiane Dinsart,

Pancreatic ductal adenocarcinoma (PDAC) represents the fourth leading cause of cancer-related death in western countries. The patients are often diagnosed in advanced metastatic stages, and the prognosis remains extremely poor with an overall 5-year survival rate less than 5 %. Currently, novel therapeutic strategies are being pursued to combat PDAC, ... Read more >>

Cancer Immunol. Immunother. (Cancer immunology, immunotherapy : CII)
[2012, 61(11):2113-2123]

Cited: 25 times

View full text PDF listing >>



Regression of glioma in rat models by intranasal application of parvovirus h-1.

Irina Kiprianova, Nadja Thomas, Ali Ayache, Manuel Fischer, Barbara Leuchs, Michèle Klein, Jean Rommelaere, Jörg R Schlehofer,

PURPOSE: In previous studies, we have shown that the apathogenic rat parvovirus H-1 (H-1PV) is capable to induce regression of advanced symptomatic rat and human gliomas in a rat model, when the virus was injected in the tumor (intracranially) or intravenously. Infection with H-1PV did not provoke any pathology in ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2011, 17(16):5333-5342]

Cited: 15 times

View full text PDF listing >>



Advertisement

Disclaimer
1.3532 s